Insulin-like peptide 5 is an orexigenic gastrointestinal hormone

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 30, 2014, Pages 11133-11138

  Grosse, Johannes ^a   Heffron, Helen ^a   Burling, Keith ^b   Hossain, Mohammed Akhter ^c   Habib, Abdella M ^d   Rogers, Gareth J ^d   Richards, Paul ^d,e   Larder, Rachel ^e   Rimmington, Debra ^e   Adriaenssens, Alice A ^d,e   Parton, Laura ^a   Powell, Justin ^a   Binda, Matteo ^f   Colledge, William H ^e   Doran, Joanne ^a   Toyoda, Yukio ^g   Wade, John D ^c   Aparicio, Samuel ^h   Carlton, Mark B L ^a   Coll, Anthony P ^e   Reimann, Frank ^d,e   O'Rahilly, Stephen ^e   Gribble, Fiona M ^d,e   more..

^a Takeda Cambridge Ltd   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f Frimorfo   (Switzerland)

^g TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APPETITE STIMULANT; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN LIKE PEPTIDE 5; PEPTIDE YY; RXFP4 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALORIC RESTRICTION; DIET RESTRICTION; ENERGY BALANCE; ENTEROENDOCRINE CELL; FOOD INTAKE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

ANIMALS; COLON; EATING; ENTEROENDOCRINE CELLS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MICE; MICE, KNOCKOUT; PEPTIDE HORMONES; PEPTIDE YY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE;

EID: 84904985324     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1411413111     Document Type: Article

References (26)

1. Mingrone G, et al. (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366(17):1577-1585.
2. Schauer PR, et al. (2012) Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366(17):1567-1576.
3. Chaudhri OB, Salem V, Murphy KG, Bloom SR (2008) Gastrointestinal satiety signals. Annu Rev Physiol 70:239-255. (Pubitemid 351738179)
4. Tolhurst G, Reimann F, Gribble FM (2012) Intestinal sensing of nutrients. Handbook Exp Pharmacol 209(209):309-335.
5. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298(2):194-206. (Pubitemid 47057766)
6. Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications. Am J Med 124(1, Suppl):S3-S18.
7. Dirksen C, et al. (2012) Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 55(7):1890-1901.
8. Habib AM, et al. (2012) Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153(7):3054-3065.
9. Egerod KL, et al. (2012) A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 153(12):5782-5795.
10. Hossain MA, et al. (2008) Synthesis, conformation, and activity of human insulin-like peptide 5 (INSL5). ChemBioChem 9(11):1816-1822.
11. Mashima H, Ohno H, Yamada Y, Sakai T, Ohnishi H (2013) INSL5 may be a unique marker of colorectal endocrine cells and neuroendocrine tumors. Biochem Biophys Res Commun 432(4):586-592.
12. Thanasupawat T, et al. (2013) INSL5 is a novel marker for human enteroendocrine cells of the large intestine and neuroendocrine tumours. Oncol Rep 29(1):149-154.
13. Shabanpoor F, Separovic F, Wade JD (2009) The human insulin superfamily of polypeptide hormones. Vitam Horm 80:1-31.
14. Burnicka-Turek O, et al. (2012) INSL5-deficient mice display an alteration in glucose homeostasis and an impaired fertility. Endocrinology 153(10):4655-4665.
15. Kong RC, Shilling PJ, Lobb DK, Gooley PR, Bathgate RA (2010) Membrane receptors: Structure and function of the relaxin family peptide receptors. Mol Cell Endocrinol 320(1-2):1-15.
16. Liu C, Lovenberg TW (2008) Relaxin-3, INSL5, and their receptors. Results Probl Cell Differ 46:213-237.
17. Liu C, et al. (2005) INSL5 is a high affinity specific agonist for GPCR142 (GPR100). J Biol Chem 280(1):292-300. (Pubitemid 40164992)
18. Reimann F, et al. (2008) Glucose sensing in L cells: A primary cell study. Cell Metab 8(6):532-539.
19. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409-1439.
20. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ (2011) GLP-1 and energy balance: An integrated model of short-term and long-term control. Nat Rev Endocrinol 7(9):507-516.
21. Neff KJ, O'Shea D, le Roux CW (2013) Glucagon like peptide-1 (GLP-1) dynamics following bariatric surgery: A signpost to a new frontier. Curr Diabetes Rev 9(2):93-101.
22. Scott R, Tan T, Bloom S (2013) Gut hormones and obesity: Physiology and therapies. Vitam Horm 91:143-194.
23. Tung YC, Piper SJ, Yeung D, O'Rahilly S, Coll AP (2006) A comparative study of the central effects of specific proopiomelancortin (POMC)-derived melanocortin peptides on food intake and body weight in pomc null mice. Endocrinology 147(12):5940-5947. (Pubitemid 44833512)
24. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics 25(9):1105-1111.
25. Trapnell C, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28(5):511-515.
26. Karolchik D, et al. (2004) The UCSC Table Browser data retrieval tool. Nucleic Acids Res 32(Database issue):D493-D496. (Pubitemid 38081706)